Literature DB >> 11747323

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.

R Torrisi1, L Baglietto, H Johansson, G Veronesi, B Bonanni, A Guerrieri-Gonzaga, B Ballardini, A Decensi.   

Abstract

The effect on the IGF system of 60 mg and 600 mg daily of raloxifene administered for 2 weeks prior to surgery was investigated in 37 postmenopausal women with breast cancer. Raloxifene significantly decreased insulin-like growth factor (IGF-I) as compared to placebo (P < 0.05) with no dose-response relationship. No significant change was observed in IGFBP-3, while the IGF-I/IGFBP-3 molar ratio was decreased by treatment, with a statistically significant effect only for the higher dose. Given that high plasma levels of IGF-I have been suggested as a risk factor for breast cancer, these findings provide further support for the potential activity of raloxifene in breast cancer prevention.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11747323      PMCID： PMC2364027          DOI： 10.1054/bjoc.2001.2191

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  28 in total

Review 1.  Insulin-like growth factor physiology and cancer risk.

Authors:  M Pollak
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

Review 2.  Role of the insulin-like growth factor family in cancer development and progression.

Authors:  H Yu; T Rohan
Journal:  J Natl Cancer Inst       Date:  2000-09-20       Impact factor: 13.506

3.  Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis.

Authors:  S Boonen; S Mohan; J Dequeker; J Aerssens; D Vanderschueren; G Verbeke; P Broos; R Bouillon; D J Baylink
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

4.  Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.

Authors:  M D Radmacher; R Simon
Journal:  J Natl Cancer Inst       Date:  2000-01-05       Impact factor: 13.506

5.  Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

Authors:  U Veronesi; G De Palo; E Marubini; A Costa; F Formelli; L Mariani; A Decensi; T Camerini; M R Del Turco; M G Di Mauro; M G Muraca; M Del Vecchio; C Pinto; G D'Aiuto; C Boni; T Campa; A Magni; R Miceli; M Perloff; W F Malone; M B Sporn
Journal:  J Natl Cancer Inst       Date:  1999-11-03       Impact factor: 13.506

Review 6.  Chemoprevention of breast cancer.

Authors:  P H Brown; S M Lippman
Journal:  Breast Cancer Res Treat       Date:  2000-07       Impact factor: 4.872

7.  Effects of high dose raloxifene in selected patients with advanced breast carcinoma.

Authors:  W Gradishar; J Glusman; Y Lu; C Vogel; F J Cohen; G W Sledge
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

8.  Serum insulin-like growth factor-I and breast cancer.

Authors:  P Toniolo; P F Bruning; A Akhmedkhanov; J M Bonfrer; K L Koenig; A Lukanova; R E Shore; A Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2000-12-01       Impact factor: 7.396

9.  Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women.

Authors:  P Garnero; E Sornay-Rendu; P D Delmas
Journal:  Lancet       Date:  2000-03-11       Impact factor: 79.321

10.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272
View more
  6 in total

Review 1.  GH receptor antagonist: mechanism of action and clinical utility.

Authors:  Sowmya K Surya; Ariel L Barkan
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

2.  Is there an estrogenic component in the metabolic syndrome?

Authors:  S Starcke; G Vollmer
Journal:  Genes Nutr       Date:  2006-09       Impact factor: 5.523

3.  Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study.

Authors:  Carol J Fabian; Lauren Nye; Kandy R Powers; Jennifer L Nydegger; Amy L Kreutzjans; Teresa A Phillips; Trina Metheny; Onalisa Winblad; Carola M Zalles; Christy R Hagan; Merit L Goodman; Byron J Gajewski; Devin C Koestler; Prabhakar Chalise; Bruce F Kimler
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-16

Review 4.  Estrogens and selective estrogen receptor modulators in acromegaly.

Authors:  Felipe H Duarte; Raquel S Jallad; Marcello D Bronstein
Journal:  Endocrine       Date:  2016-10-04       Impact factor: 3.633

Review 5.  Raloxifene: a review of its use in the prevention of invasive breast cancer.

Authors:  Marit D Moen; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene.

Authors:  Benedito B da Silva; Daniel S Moita; Cleicilene G Pires; Edílson C Sousa-Junior; Alesse R dos Santos; Pedro V Lopes-Costa
Journal:  Int Semin Surg Oncol       Date:  2007-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.